Hill Emily Luisa sold $148K of REPL

Hill Emily Luisa (Chief Financial Officer) sold 11,448 shares of Replimune Group, Inc. (REPL) at $12.97 ($0.15M total) on 2026-08-10.

Original reporting
SEC EDGAR · Hill Emily Luisa
Published Aug 12, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide new guidance, trial results, or regulatory developments.

03

What to watch

The filing does not state motivations, option exercises, or other concurrent transactions; without context, the signal strength is weak.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Replimune Group, Inc.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune CFO Hill Emily Luisa filed a Form 4 selling 11,448 shares at $12.97 on 2026-08-10, totaling $148,480.56.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than driven by new company fundamentals.

Evidence & confidence

The filing discloses transaction details (size, price, post-sale holdings) but provides no new operational, financial, or regulatory information about REPL.

Market effects

Minimal; insider sales typically do not reset sector expectations without accompanying company-specific news.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine for diversification or tax planning, and the absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • Replimune Group, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Hill Emily Luisa

    Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.